1,8-Cineole

1,8-Cineole is a monoterpene compound found in eucalyptus oil that demonstrates anti-inflammatory and bronchodilatory effects through modulation of inflammatory cytokines. Clinical trials show efficacy for respiratory conditions including COPD exacerbation prevention and asthma control improvement.

Category: Compound Evidence: 4/10 Tier: Moderate (some RCTs)

Origin & History

1,8-Cineole (eucalyptol) is a naturally occurring monoterpene oxide with a camphoraceous odor, primarily extracted from Eucalyptus globulus leaves, as well as rosemary and tea tree plants. Production involves steam distillation of plant materials, yielding a colorless to pale yellow liquid that is purified to ≥99% for pharmaceutical applications.

Historical & Cultural Context

1,8-Cineole has been used for centuries in Australian Aboriginal medicine from Eucalyptus leaves for respiratory infections, coughs, and pain relief. Since the 19th century, it has been incorporated into European phytotherapy for bronchitis and sinusitis, with modern clinical validation supporting these traditional respiratory applications (PMID: 39937641, 24831245).

Health Benefits

• Reduces preoperative anxiety: RCT (n=62) showed significant STAI score reduction with 5-minute inhalation (PMID: 25028591)
• Prevents COPD exacerbations: Clinical trials demonstrated reduced exacerbations with 200mg 3x daily oral dosing (PMID: 24831245)
• Improves asthma control: Trials showed enhanced control through anti-inflammatory and mucolytic mechanisms (PMID: 24831245)
• Enhances cognitive performance: Human studies found plasma levels correlated with improved cognitive speed and accuracy (PMID: PMC3736918)
• Anti-inflammatory potential for IBD: Mouse model studies showed reduced colitis inflammation, though human RCTs pending (PMID: 37047133)

How It Works

1,8-Cineole inhibits pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 while reducing nuclear factor-κB activation. It enhances mucociliary clearance by stimulating chloride secretion and exhibits bronchodilatory effects through smooth muscle relaxation. The compound also modulates GABA neurotransmission, contributing to its anxiolytic properties.

Scientific Research

Clinical evidence includes a randomized controlled trial (n=62) demonstrating anxiety reduction with 1,8-cineole inhalation before medical procedures (PMID: 25028591), and multiple trials showing COPD and asthma management benefits at 600mg/day oral dosing (PMID: 24831245). Additional research correlates plasma levels with cognitive enhancement (PMID: PMC3736918), though no meta-analyses were identified in the current data.

Clinical Summary

Randomized controlled trials demonstrate 1,8-cineole's efficacy across multiple conditions. A 62-participant RCT showed significant STAI anxiety score reduction with 5-minute inhalation (PMID: 25028591). Clinical trials confirm reduced COPD exacerbations with 200mg three times daily oral dosing (PMID: 24831245). Additional trials indicate improved asthma control, though sample sizes remain moderate and longer-term safety data is limited.

Nutritional Profile

1,8-Cineole (also known as eucalyptol) is a pure monoterpenoid compound (C10H18O, molecular weight 154.25 g/mol), not a food ingredient, therefore it has no conventional macronutrient or micronutrient profile. It is a bicyclic ether comprising 100% bioactive monoterpene by definition when in isolated form. Key physicochemical properties relevant to bioavailability: lipophilic (logP ~2.74), boiling point 176°C, density 0.921 g/mL. Bioactive compound data: when derived from eucalyptus oil, 1,8-Cineole typically constitutes 60–90% of the essential oil by volume. Oral pharmaceutical dosing studied at 200mg capsules (Soledum/Cineole formulations) 3x daily (600mg/day total). Inhalation bioavailability is rapid, with detectable blood levels within minutes of exposure; oral bioavailability is estimated at approximately 80–90% due to high lipophilicity and rapid GI absorption. It undergoes hepatic CYP450 metabolism (primarily CYP2B6, CYP3A4) to hydroxylated metabolites (2-hydroxy-1,8-cineole, 3-hydroxy-1,8-cineole). Half-life is approximately 2 hours. No fiber, protein, vitamins, or minerals are present as it is a single isolated phytochemical compound. Caloric contribution is negligible at therapeutic doses.

Preparation & Dosage

Clinically studied dosages include: Inhalation - 1% solution or pure compound via mask for 5 minutes for anxiety; Oral - 200mg three times daily (600mg/day) for COPD/asthma management; standardized preparations typically contain ≥99% pure 1,8-cineole or eucalyptus oil with 70-85% content. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Eucalyptus oil, Rosemary extract, Limonene, N-acetylcysteine, Quercetin

Safety & Interactions

1,8-Cineole is generally well-tolerated at therapeutic doses, with occasional reports of gastrointestinal upset and skin irritation from topical use. No significant drug interactions have been documented in clinical studies. Safety during pregnancy and lactation has not been established through controlled trials. Individuals with epilepsy should exercise caution due to potential CNS effects at high doses.